Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.
about
Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshopIn vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging.Use of MRI in preoperative planning for women with newly diagnosed DCIS: risk or benefit?Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation.
P2860
Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Biomarkers predicting recurren ...... u treated by lumpectomy alone.
@en
Biomarkers predicting recurren ...... u treated by lumpectomy alone.
@nl
type
label
Biomarkers predicting recurren ...... u treated by lumpectomy alone.
@en
Biomarkers predicting recurren ...... u treated by lumpectomy alone.
@nl
prefLabel
Biomarkers predicting recurren ...... u treated by lumpectomy alone.
@en
Biomarkers predicting recurren ...... u treated by lumpectomy alone.
@nl
P2860
P356
P1476
Biomarkers predicting recurren ...... u treated by lumpectomy alone.
@en
P2093
D Craig Allred
P2860
P304
P356
10.1093/JNCI/DJQ118
P407
P577
2010-04-28T00:00:00Z